Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 8-K (Current Report)
Date of Report: November 10, 2021
Reporting Period: Third quarter ended September 30, 2021
Status: Emerging Growth Company
Key Financial Metrics
This Form 8-K serves as a notification of the release of financial results and an investor presentation. The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the press release (Exhibit 99.1) and investor presentation (Exhibit 99.2) referenced within the document.
Material Changes
The filing announces the issuance of results of operations and financial condition for the third quarter of 2021. No specific material changes or comparative data are provided within the body of this 8-K text.
Guidance, Outlook, and Risks
Management Commentary: The company released an updated investor presentation on November 10, 2021, intended for use in investor meetings.
Legal Disclaimer: The information furnished in this 8-K (including the press release and investor presentation) is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2021 revenue, net loss, and cash burn figures.
- Examine Exhibit 99.2 (Investor Presentation) for updated operational milestones and strategic outlook.
- Verify the company's cash position and runway based on the detailed financial statements in the referenced exhibits.
- Confirm any new partnership announcements or clinical trial updates mentioned in the press release.